Dihydromyricetin Exhibits Antitumor Activity in Nasopharyngeal Cancer Cell Through Antagonizing Wnt/β-catenin Signaling

Ling Ye*1, Gendi Yin*2, Miaohua Jiang1, Bo Tu1, Zhicheng Li2, and Yiming Wang1

Abstract

Background: Cancer stem cells (CSCs) have been demonstrated to play a vital role in a diversity of biological processes in cancers. With the emergence of new evidence, the important function of CSCs in the formation of multidrug resistance of nasopharyngeal cancer has been demonstrated. Dysregulated Wnt/β-catenin signaling pathway is an important contributor to chemo-resistance and maintenance of CSCs-like characteristics. This research aims to investigate comprehensively the function of dihydromyricetin (DMY), a natural flavonoid drug, on the cisplatin (cis) resistance and stem cell properties of nasopharyngeal cancer. Methods: In this study, the functional role of DMY in nasopharyngeal cancer progression was comprehensively investigated in vitro and in vivo, and then its relationship with CSCs-like phenotypes and multiple oncogenes was analyzed. Results: In parallel assays, the growth inhibitory action of cis was enhanced by the addition of DMY in cis-resistant nasopharyngeal cancer cell lines (Hone1/cis and CNE1/cis). Functional assays showed that DMY markedly diminished the stem cell properties of nasopharyngeal cells, such as colony and tumor-sphere formation. In vivo data showed that the growth of Hone1 CSCs formed tumor xenograft was inhibited significantly by the administration of DMY. Additionally, DMY could impair the Wnt/β-catenin signaling pathway and regulate the expression of downstream proteins in nasopharyngeal cancer cells. Conclusions: Our study clarified the anti-tumor activity of DMY through blocking the Wnt/β-catenin signaling pathway in nasopharyngeal cancer. Therefore, DMY could be a novel therapeutic agent for nasopharyngeal cancer treatment.

Keywords
dihydromyricetin, Wnt/β-catenin signaling, nasopharyngeal cancer, cancer stem cell

Submitted August 2, 2020; revised January 1, 2021; accepted January 11, 2021.

Introduction

Nasopharyngeal cancer is a highly endemic carcinoma in Southern China and Southeast Asia, but is infrequent in Europe as well as in America. In recent years, an average of 86,000 new cases of nasopharyngeal cancer has been diagnosed worldwide and approximately 50,000 deaths annually.1,2 Currently, in spite of the endeavor and progress on treatment strategies of nasopharyngeal cancer, cisplatin (cis)- based chemotherapy concurrently with or after radiotherapy is still the main remedy for this disease. Whereas continuous exposure to cis can cause serious adverse effects, and many patients with nasopharyngeal cancer exhibit a poor response to systematic chemotherapy, the long-term clinical prognosis of nasopharyngeal cancer patients still remains poor. Among these influencing factors, the production of innate or acquired resistant cancer

*contributed equally to this work

Corresponding Authors: Ling Ye, Department of Oncology, The First Affiliated Hospital of Jinan University, NO.613 Huangpu road, Guangzhou, Guangdong 510632, China. Email: 32600972@qq.com

Gendi Yin, Department of Otolaryngology Head Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China. Email: entygd@163.com

Bo Tu, Department of Otolaryngology Head Neck Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510632, China. Email: 343865083@qq.com

Creative Commons Non-Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
cells is the major clinical impediment for the curative effect. Accumulating evidence supports that nasopharyngeal cancer cells harbor a subgroup of tumor cells with stem cell features, termed cancer stem cells (CSCs). The CSCs are characterized by preferential expression of stem cell markers, increased self-renewal ability, multi-lineage differentiation potential, expression of drug-resistance genes and promoted tumorigenicity in vivo. Consequently, CSCs are highly capable of increasing nonresponsiveness to chemoradiotherapy or reconstituting tumor after successful therapy. Furthermore, it has been well documented that CSCs are related to a higher incidence of tumor invasion and metastases. Therefore, development of novel therapeutic modalities on CSCs eradication is urgently needed to fight against cancer development and enhance the efficacy of cancer therapies.

The Wnt/β-catenin signaling pathway regulates the expression of numerous downstream genes that are associated with embryonic development as well as tissue homeostasis. Aberrant Wnt/β-catenin signaling has been implicated in the CSCs-like phenotypes of many different human cancers, including nasopharyngeal cancers. Wnt/β-catenin signaling is activated by Wnt ligands binding to a Frizzled receptor as well as lipoprotein receptor-related protein 5/6. Wnt stimulates the activation of Fzd, which triggers phosphorylation of 1 or more cytoplasmic motifs of LRP5/6. Subsequently, phosphorylated LRP5/6 enhances the interaction between DVL and AXIN, which destabilizes the catenin destruction complex composed of AXIN, APC, CK1, and GSK-3β. The destruction complex can phosphorylate β-catenin, which lead to β-catenin accumulation, nuclear translocation, and eventually modulation of the expression of Wnt target genes, such as CD44, cyclin D, c-Myc, Survivin, and fibronectin. Given that the Wnt/β-catenin signaling pathway is implicated in oncogenicity, self-renewal, and therapy-resistance, a therapeutic intervention that targets the Wnt/β-catenin signaling pathway may provide an efficacious approach towards the eradication of human malignancies, specifically nasopharyngeal cancer.

Dihydromyricetin (DMY), a natural flavonoid from Ampelopsis grossedentata and waxberry, has been shown to have strong anti-inflammatory, antioxidant, antibacterial, and antithrombotic abilities. Moreover, various studies have shown the potent cytotoxic activity of DMY and its biological targets in various human carcinoma cell lines. DMY has been investigated in combination with other agents to evaluate their synergistic antitumor effect which will result in fewer side effects. Recent studies demonstrated that DMY has the ability to modulate the Wnt/β-catenin pathway by binding to βCN, COLIA1 and RUNX2 proteins, which are involved in maintenance of mesenchymal stem cells. Although DMY and its structural modifications have potential application in cancer chemotherapy, the pharmacological effect of DMY on the CSCs-like phenotypes of nasopharyngeal cancer has not been reported.

In this study, the functional role of DMY in nasopharyngeal cancer progression was comprehensively investigated in vitro and in vivo, and then its relationship with CSCs-like phenotypes and multiple oncogenes was analyzed. Our results identified DMY as a novel Wnt/β-catenin signaling antagonist that exerts potent anti-CSCs activity against nasopharyngeal cancer.

**Materials and Methods**

**Cell Culture**

Two human nasopharyngeal cancer cell lines (Hone1 and CNE1) as well as the non-malignant nasopharyngeal epithelial cell line NP69 were purchased from Shanghai Honsun Biological Technology Co., Ltd. The cells were seeded in 6-well plates at $1 \times 10^5$ cells/cm² in high glucose DMEM medium (containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin) at 37 °C and 5% CO₂. The cells in 3rd to 8th generation and logarithmic phase were used for experiment.

**Construction of cis-resistant Nasopharyngeal Cancer Cell Lines**

To establish cis-resistant nasopharyngeal cancer models, Hone1 and CNE1 cells were exposed to gradually increasing doses of cis in vitro as described previously. The constructed cis-resistant cell lines were named Hone1/cis and CNE1/cis. Cis-resistant nasopharyngeal cancer cells were maintained in cis-free medium for 7 days prior to the experiments.

**Cell Viability Assay**

After nasopharyngeal cancer cells were plated and treated with DMY and/or cis, 10 µL of MTT (5 mg/mL) was added into cell for 4 hours at 37°C. Old medium was removed and DMSO was added into cells for 20 minutes. The absorbance at 560 nm was detected by enzyme linked immune detector (Thermo Scientific Multiskan GO, Vantaa, Finland) at a wavelength of 490 nm. The IC50 value was calculated as the cis concentration causing 50% decrease in cell viability.

**Flow Cytometry Analysis for Apoptosis**

After cells were incubated with or without medium containing DMY for 24 hours, cells were washed by PBS 2 times and fixed with 75% ethanol at −20°C overnight. After PBS washing again, cells were stained with FITC-Annexin V and PI (Bio-Rad) for 25 minutes in dark. Flow cytometry
(FACS Calibur and LSR™ II Flow Cytometer; BD Pharmingen) was used to detect the apoptotic rate.

**ALDEFLUOR Assay**

The identification of aldehyde dehydrogenase (ALDH) activity was evaluated after incubation of nasopharyngeal cancer cells with or without DMY, using an ALDEFLUOR™ kit (Stem Cell Technologies, Vancouver, British Columbia, Canada) following the instruction provided by the kit manufacturer. The fluorescence intensity of the stained cells was detected by flow cytometer.

**Colony Formation Assay**

Cells (1000 cells/well) were seeded in triplicate and cultured under normal culture conditions of 5% CO₂ at 37°C for 6 days. Colonies were then fixed with 4% paraformaldehyde and stained with Giemsa solution, and colonies (>50 cells) were then counted.

**Western Blot Analysis**

Briefly, cells (2 × 10⁶) were seeded in 6-well plate and dissociated with NP-40 lysis buffer (Beyotime Biotechnology Company, Shanghai, China) at 4°C. The extracted protein from cells was separated on SDS-PAGE gels and transferred to nitrocellulose membranes at 100mA for 2 hours. All membranes were blocked in 3% skim milk powder for 3 hours, and subsequently incubated with primary antibodies overnight at 4°C. The antibodies against Nanog (376915), ABCG2 (377176), C-Myc (47694), Wnt1 (514531), and β-actin (58676) were obtained from Santa Cruz Biotechnology (St Louis, Mo, USA). The antibodies against β-catenin (ab32572), active β-catenin (ab227499), Survivin (ab76424), p-STAT3 (ab32143), STAT3 (ab68153), and Axin2 (ab109307) were purchased from Abcam Biotechnology (Cambridge, MA, USA). Antibodies specific for p-LRP6 (2568), LRP6 (2560), cyclin D (2922), LaminA/C (4777), OCT4 (2750), and SOX2 (3579) were obtained from Cell Signaling Technology (Danvers, MA, USA). After this, the membranes were probed with the peroxidase-labeled secondary antibodies. Membranes were visualized after ECL and analyzed using Image Lab 3.0 (Bio-Rad Laboratories, Inc.) according to the manufacturer’s protocol.

**Sphere-forming Assay**

Sphere formation from nasopharyngeal cancer cells was described previously. Hone1 and CNE1 cells for sphere formation were resuspended in Ham’s F-12 medium, 20 ng/mL basic FGF (Fisher Scientific), 20 ng/mL EGF (Sigma) and 4 ng/mL Heparin (Sigma). Cells (5000 cells/mL) were cultured in ultralow attachment 6-well plates (Corning, NY, USA) and then cultured in cell incubator for 7 days. The tumor-spheres were then incubated with vehicle or DMY for 24 hours. Images of representative tumor-spheres were photographed and analyzed under inverted microscope.

**Immunofluorescence Assay**

After nasopharyngeal cells were treated with or without DMY for 24 hour, cells were fixed with 5% paraformaldehyde for 10 minutes and blocked using 5% BSA as well as 0.1% Triton X-100 in PBS for 1 hour. Afterwards, cells were incubated with primary antibody at 4°C overnight. Cells were then washed with PBS for 15 minutes and incubated with the corresponding secondary antibody for 1 hour in darkness. Cells were finally washed with PBS for 15 minutes and incubated with Hoechst for 15 minutes at darkness. Cells were observed using a fluorescent microscope (Zeiss, Göttingen, Germany; Imager M2).

**TOP Flash Luciferase Reporter Assay**

TOP flash and TCF4 were designed and synthesized by Sangon Biotech Co., Ltd. Hone1 cells were cultured in 96 well plates (20 000 cells/50 µL) and transfected with 20 ng of TOP flash. Following that, cells were transfected with Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA) as the manufacturer’s protocol. The cells were lysed using FastBreak™ Cell Lysis Reagent (Promega Corporation, Madison, WI, USA) and the luciferase activities were assayed by Dual-Luciferase Reporter assay system (Promega Corporation).

**Subcutaneous Implantation of Nasopharyngeal Cancer**

4–6-week-old BALB/C-nu/nu nude male mice were maintained in pathogen-free cages. 1 × 10⁴ Hone1 CSCs mixed with 100 µL of Matrigel were injected subcutaneously into the mid-abdominal of nude mice. After the tumors reached 50 mm³, all the animals were treated with DMY (5 mg/kg given twice a week by intraperitoneal injection or oral gavage for 28 days). All the mice were sacrificed after 40 days of inoculation, and the xenografts were humanely excised and weighed.

**Immunolocalization of Ki-67 in Tumor Samples**

Tissues were formalin-fixed and paraffin-embedded, and then sections were made in 4 µm. Those sections were heated at the oven at 75°C for 30 minutes and deparaffinized...
in xylene, rehydrated in alcohol (100%, 100%, 95%, 85%, 75%). Immunohistochemical (IHC) assays were introduced according to the specifications of IHC assays (Cell Signaling Technology, Danvers, MA, USA). Briefly, antigen was retrieved by citric acid buffer in a microwave for 15 minutes. The antigen is then cooled down to room temperature. Endogenous peroxidase was blocked using blocking reagent for 5 minutes. After that, sections were incubated with anti-Ki-67 antibody (Sigma, Co, USA) in 4°C overnight. The second day, sections were incubated with secondary antibody-HPA (Sigma, Co, USA) for 1 hours. Then the sections were stained with Diaminobenzidine (DAB, Cell Signaling Technology, Pudong, Shanghai, China) for 5 minutes. The images were collected by microscope (Nikon, Tokyo, Japan).

**Terminal Deoxynucleotidyl Transferase–mediated dUTP Nick end Labeling (Tunel) Assay**

The apoptosis of tumor tissues was evaluated using an In situ cell death detection kit from Roche diagnostics as per manufacturer’s protocols strictly. Tunel reaction was viewed and photographed using a light microscope (Olympus BX51, Shinjuku, Japan) by 2 different pathologists unaware of the xenograft tumor groups. Average number of Tunel-positive apoptotic cells of 10 randomly chosen fields from each treatment groups were counted.

**Statistical Analysis**

Data were analyzed using the SPSS 21.0 software package. All data were expressed in means and standard deviations. Quantitative variables between groups were analyzed using either t-test or ANOVA. *P* < .05 was considered statistically significant.

**Results**

**DMY Inhibits the Viability as Well as Induces Apoptosis in Nasopharyngeal Cancer Cells**

To examine the inhibitory effect of DMY on the viability of nasopharyngeal cancer cells. Hone1 and CNE1 cells were treated with gradient doses of DMY (5-200 µmol/L) for 24 hours. Treatment with DMY dose-dependently reduced the viability of nasopharyngeal cancer Hone1 and CNE1 cells (Figure 1a). In contrast, DMY (5-50 µmol/L) exerted no toxic effect on the growth of nasopharyngeal epithelial cell line NP69 in vitro. Furthermore, 10 µmol/L of DMY exerted a time-dependent inhibitory effect on the viability of nasopharyngeal cancer cells, so 10 µmol/L of DMY was selected for use as the standard concentration for subsequent in vitro experiments. To determine whether DMY induces nasopharyngeal cancer cell apoptosis, flow cytometric assay was employed to detect the apoptosis following DMY stimulation.

Figure 1c shows that DMY induced apoptosis in 2 nasopharyngeal cancer cell lines compared to untreated cells. These data disclosed that DMY was an effective growth inhibitor of nasopharyngeal cancer cells as a single agent, and the therapeutic efficacy of DMY is cancer cell-selective.

**Antitumor Activity of cis is Augmented by DMY in Chemoresistant Nasopharyngeal Cancer Cell Lines**

In this study, by exposing Hone1 and CNE1 cells to increasing doses of cis for 3 months, cis-resistant nasopharyngeal cancer cell lines (Hone1/cis and CNE1/cis) were established successfully. As shown in Figure 2a, the IC50 values of cis in Hone1/cis and CNE1/cis cells are nearly twelve times higher than their parental cell lines. Subsequent experiments were focused on the effects of combining DMY with cis on the viability of nasopharyngeal cancer cells. Following treatment with either DMY (10 µmol/L) or cis (0.2 µmol/L) alone for 24 hours resulted in 12% to 36% loss of viable nasopharyngeal cancer cells. However, the combination of DMY with cis exerted notably greater inhibition of viability than either single drug. Cotreatment of DMY and cis caused 42% to 50% loss of viable cells in all nasopharyngeal cancer cell lines (Figure 2b). Furthermore, statistical analysis demonstrated that cis-resistant cells treated with DMY plus cis showed a synergistic effect with a combination index (CI) less than 1. However, the parental cell lines were not very sensitive to this cotreatment. DMY had an additive effect on cis (CI = 1). It could be possible that DMY has an enhanced effect on the chemoresistant cancer cells. Additionally, active β-catenin expression was promoted in both cis-resistant nasopharyngeal cancer cell lines in comparison with their parental cell lines (Figure 2c), suggesting the underlying molecular association between β-catenin and nasopharyngeal cancer chemoresistance. Moreover, the results displayed that cis has no effect on the expression of active β-catenin in both Hone1/cis and CNE1/cis cells, whereas DMY (10 µmol/L) alone or combined with cis substantially reduced the level of active β-catenin (Figure 2d). Taken together, these results showed that DMY negatively regulated the chemoresistance of nasopharyngeal cancer cells through downregulation of β-catenin.

**DMY Reduces the Stem Cell Like Phenotype of Nasopharyngeal Cancer Cells**

Increasing evidence showed that CSCs are characterized by promoted chemoresistance and tumorsphere-formation efficiency, and implicated in cancer initiation, decreased treatment response and metastasis. To better understand the mechanisms of DMY on the growth of...
inhibition of nasopharyngeal cancer cells, we next attempted to determine the effect of DMY on the CSCs-like phenotypes in Hone1 and CNE1 cells. First, the sphere formation assay was employed to establish Hone1 and CNE1 CSCs by cultivating cells in serum-free conditions. CSCs can be characterized by their markers: OCT4, SOX2, and increased ALDH1 activity. Subsequently, Hone1 CSCs were testified by immunofluorescence analysis with 2 stem cell markers, OCT4 and SOX2. Growing evidence supports that the up-regulation of OCT4 and SOX2 are highly correlated with cell pluripotency and self-renewal. We found that the tumorspheres formed from single cells were positive for 2 stem cell markers (Figure 3a). The influences of DMY on the stem cell properties of nasopharyngeal cancer cells were then explored. Flow cytometry assay revealed that DMY (10 μmol/L) markedly reduced ALDH1 activity in both Hone1 and CNE1 cells (Figure 3b). In addition, the effect of DMY on the tumorsphere formation of Hone1 and CNE1 cells was conducted. As is shown in Figure 3c, treatment with DMY (10 μmol/L) notably decreased the tumorsphere size and disintegration in both Hone1 and CNE1 cells. The ability of colony formation is 1 of the hallmarks of CSCs, and then the effect of DMY on the
colony formation of nasopharyngeal cancer cells was investigated. As shown in Figure 3d, compared to untreated cells, treatment with DMY (10 µmol/L) markedly decreased the number of colonies in both nasopharyngeal cancer cell lines. These results coincided with western blot data showing significant decreases in the levels of α-activity β-catenin.
selected panel of stemness markers (Nanog, OCT4, SOX2, ABCG2, and C-Myc) in Hone1 and CNE1 cells after DMY (10 μmol/L) treatment (Figure 3e). These in vitro results suggested that DMY was a negative regulator on the stem cell-like phenotype and self-renewal capacity of nasopharyngeal cancer cells.

**Figure 3.** DMY significantly attenuates the stem cell-like phenotype of Hone1 and CNE1 cells. (A) The positive expression of stem cell markers (OCT4 and SOX2) are observed in cytoplasm of Hone1 CSCs. (B) FACS images of ALDH1 activity in Hone1 and CNE1 cells treated with DMY for 24 hour. (C) Respective photo-images demonstrating DMY markedly decrease the size and number of tumorspheres in Hone1 and CNE1 cells. (D) DMY treatment inhibited the colony forming ability of Hone1 and CNE1 cells. (E) The relative protein levels of Nanog, OCT4, SOX2, ABCG2, and C-Myc were determined by western blot in Hone1 and CNE1 cells after treated with DMY or vehicle. Similar results were obtained in 3 independent experiments. ***P < .001. Scale bar: 20 μm.
DMY Inhibits the CSCs-associated Oncogenic Wnt/β-catenin Signaling Pathway

A previous study has disclosed that DMY was associated with the properties of mesenchymal stem cells by regulating the Wnt/β-catenin pathway. Therefore, we next aimed to analyze the probable β-catenin-mediated efficacy of DMY in nasopharyngeal cancer CSCs. The regulatory effect of DMY on β-catenin pathway was investigated by using the TOP flash reporter assay, which yields a better detection of β-catenin signaling pathway by exploring the nuclear β-catenin driven transcription activation. The results demonstrated that DMY (10 µmol/L) treatment markedly decreased the TOP Flash luciferase activity in Hone1 CSCs (Figure 4a). Emerging evidence also indicated that the translocation of unbound β-catenin from the plasma-membrane position to the cell nucleus resulting in activation of multiple Wnt downstream factors. So we next investigated whether DMY could disrupt the localization of β-catenin by immunofluorescent staining of β-catenin in Hone1 CSCs (Figure 4b). Our results demonstrated that β-catenin is present in both the cytoplasm and nucleus under normal conditions, whereas DMY treatment (10 µmol/L) significantly attenuated the translocation of β-catenin to the nucleus in Hone1 CSCs. Similarly, immunoblotting data coincides with the result of immunofluorescence, demonstrating that DMY treatment could reduce the nuclear expression of β-catenin in nasopharyngeal CSCs.

Phosphorylation of transmembrane receptor LRP6 is a vital Wnt co-receptor for the Wnt/β-catenin signaling pathway. As an important member of the STAT family, STAT3 has been implicated in CSCs phenotypes and exhibits sustained activity in various cancers. Additionally, transcription factors involved in stem cell self-renewal and malignant phenotypes, such as Nanog, OCT4, and SOX2, can be regulated by the phosphorylation of STAT3. Given the inhibitory effect of DMY on the phenotypes of nasopharyngeal CSCs, we further investigated the effect of DMY on the expression of Wnt/β-catenin pathway-related proteins. Treatment with DMY (10 µmol/L) decreased the levels of Wnt, phosphorylated LRP6, Axin2, Survivin and cyclin D in both Hone1 and CNE1 CSCs (Figure 4c). Furthermore, we found that the phosphorylation of STAT3 at Tyr705 in both nasopharyngeal cancer CSCs was markedly inhibited by DMY treatment, whereas the phosphorylation of STAT3 at Ser727 was not greatly changed in comparison with the control group. Together, these findings support the hypothesis that the inhibitory effect of DMY on the Wnt/β-catenin and STAT3 signaling pathways in nasopharyngeal CSCs is the underlying mechanism involved in its anti-tumor effect.

Discussion

At present, the incidence of nasopharyngeal cancer in China has been growing year by year, and is now the tenth leading cause of cancer-related death in China. The most effective adjuvant therapy of nasopharyngeal cancer is chemotherapy, and cisplatin is widely used in its clinical treatment.
Figure 4. DMY inactivates Wnt/β-catenin signaling pathway and STAT3 in nasopharyngeal CSCs. (A) The regulatory effect of DMY on the TCF/LEF reporter activity in Hone1 CSCs was evaluated by using the TOP flash reporter assay. (B) β-catenin cellular localization was observed by immunofluorescence assay (200×). (C) Western blot results of endogenous Wnt/β-catenin pathway-related proteins as well as the activation of STAT3 in Hone1 and CNE1 CSCs. Results are reported as the mean ± SD of 3 independent experiments, **P < .01. Scale bar: 20 µm.

However, the chemoresistance of cancer cells to cis causes poor prognosis, recurrence and metastasis. Thus, it is imminently needed to discover the key players implicated in chemoresistance and develop new therapeutic strategies with less toxicity and high anti-cancer efficacy. Natural products probably represent an ideal source to discover
novel low toxic and effective drugs for the treatment of human malignancies. DMY has shown many health-promoting effects, including anti-cancer effects in a broad range of cancer cells. Mechanistic analysis demonstrated that DMY promoted intracellular peroxide and sustained the activation of ERK1/2 and JNK1/2 signaling pathways. DMY can inhibit cancerous cells proliferation via AMPKa and p38 activation. This is the first report describing the therapeutic benefit and mechanism of DMY against nasopharyngeal cancer cells, by targeting CSCs. Furthermore, the viability of normal nasopharyngeal epithelial cells was not significantly affected by DMY (50 μmol/L) for 24 hours, and the administration of DMY did not greatly alter animal weight, demonstrating a moderate dose of DMY exerted no serious toxicity to normal cells. Our findings suggest that the herbal drug DMY is a promising candidate for nasopharyngeal cancer treatment.

The aberrant expression of Wnt/β-catenin signaling is common in many different types of cancers. The nuclear translocation of β-catenin promotes the Wnt pathway, which in turn increases the downstream oncogenic activity, directly linking to enhanced cell proliferation and promoting cell motility and tumor invasion. This study showed that DMY, a flavonoid with previously unknown function in nasopharyngeal cancer cell, exerted a negative regulatory effect on viability of established nasopharyngeal cancer cell lines, Hone1 and CNE1, as well as the Hone1/cis and CNE1/cis cell lines, which are enriched for CSCs. We found that DMY could partly reverse the resistance of cis-resistant nasopharyngeal cancer cells to cis by downregulation of β-catenin, suggesting that DMY has an enhanced inhibitory effect on the more stem-like cells. However, little is known about DMY in stem cells, except for a study demonstrating that DMY can regulate the biological behavior of

Figure 5. In comparison with oral gavage, intraperitoneal administration of DMY markedly and more efficiently inhibits the growth of Hone1 CSCs formed tumor xenograft. (A) Average mouse weights of 3 groups before and after the experiments. (B) Representative images of xenograft tumor showing the therapeutic benefit of DMY. (C) Immunohistochemical analysis of Ki-67 in tumor xenografts. (D) The apoptosis of tumor xenograft was analyzed by Tunel assay. Similar results were obtained in 3 independent experiments. **P < .01. Scale bar: 20 μm.
mesenchymal stem cells by modulating the Wnt/β-catenin pathway. Therefore, we propose that DMY can affect the stem cell properties of nasopharyngeal cells, and this hypothesis was supported by our observations.

In this current work, we found that DMY is able to significantly impede colony-forming and tumorsphere-forming population of nasopharyngeal CSCs. Furthermore, we disclosed that this inhibition of nasopharyngeal CSC malignant phenotypes is associated with the concurrent significant downregulation in the levels of stemness markers (Nanog, OCT4, SOX2, ABCG2, and C-Myc) in Hone1 and CNE1 cells. Consistent with earlier investigations demonstrating that the Wnt/β-catenin pathway plays an indispensable role in keeping the CSCs pluripotency and self-renewal by regulation of Nanog, OCT4, SOX2, ABCG2, and C-Myc. As an intracellular surrogate CSCs marker, ALDH1 is implicated in therapy resistance and promotes the self-renewal phenotype. In the present study, we showed that DMY significantly diminished the pool of ALDH1-positive cells in both Hone1 and CNE1 cells. These findings could strongly support the idea that DMY might be used as a CSCs inhibitor in nasopharyngeal cancer. Further experiments were used to test the hypothesis that the anti-tumor activity of DMY in nasopharyngeal cancer is sustained in vivo. The results in vivo disclosed that treatment with DMY markedly suppresses nasopharyngeal CSCs-induced xenograft tumor growth. Our in vivo findings are in accordance with the changes observed in the cultured cells. The data could strongly support the idea that DMY more directly and importantly affects the stemness of nasopharyngeal cancer cells both in vitro and in vivo, and DMY might be employed as a “supplement” in cis-based chemotherapy to improve the overall response rate to cis. Interestingly, we further demonstrated that compared with parenteral gavage, the intraperitoneal administration of DMY led to an augmented antitumor efficacy on the growth of xenograft tumor. One explanation for this could be that intraperitoneal implement of DMY avoids the first-pass effect of liver metabolism.

Among the family of STAT proteins, STAT3 plays a crucial role in the mediation of various fundamental functions. Phosphorylated STAT3 has been reported to be important in the regulation of stem cell phenotypes. Emerging evidence has suggested that the Wnt/β-catenin pathway mediates self-renewal and stemness properties of CSCs. Several Wnt target genes have been regarded as CSCs markers, including Nanog and CD133. Prior studies have shown that interactions between the Wnt/β-catenin signaling pathway and STAT3 act as a vital modulator in nasopharyngeal carcinogenesis. More importantly, activated β-catenin has been shown to be highly involved in the expression of STAT3 at gene transcription and translation levels, and the phosphorylation of STAT3 induces the nuclear transposition of β-catenin.

Figure 6. DMY suppresses the Wnt/β-catenin signaling pathway and inactivates of STAT3 in vivo. (A) β-catenin cellular localization in tumor xenograft was observed by immunofluorescence assay. (B) The differential effects of oral and intraperitoneal administration of DMY on the expression of Wnt/β-catenin pathway-related proteins and STAT3 in Hone1 CSCs formed tumor xenograft. Results are reported as the mean ± SD of 3 independent experiments. Scale bar: 50 µm.
Thus, targeting the Wnt/β-catenin pathway and/or STAT3 can potentially eliminate CSCs phenotypes, resulting in complete cure of the cancer. In the present study, we found that DMY not only inhibits the Wnt/β-catenin signaling pathway, but also reduces STAT3 phosphorylation at Tyr705 site both in vitro and in vivo nasopharyngeal CSCs. The data indicated that DMY suppressed the CSCs phenotypes of nasopharyngeal cancer by the STAT3 and Wnt/β-catenin signaling pathway.

In this scenario, our current findings highlight the therapeutic potential of DMY in the treatment of nasopharyngeal cancer, especially for reversal nasopharyngeal CSCs-associated cis resistance. Mechanistically, we demonstrated that DMY acts as a disruptor of Wnt/β-catenin and STAT3 signaling pathways, thus mediating the CSCs phenotypes of nasopharyngeal cancer. In this way DMY, which targets multiple pathways and has an existing safety property, may be a novel antineoplastic agent for future nasopharyngeal cancer treatment.

Author Contributions

(I) Conception and design: All authors; (II) Administrative support: Ling Ye, Gendi Yin; (III) Provision of study materials or patients: Ling Ye, Bo Tu, Yi-ming Wang; (IV) Collection and assembly of data: Ling Ye, Gendi Yin, Zhicheng Li; (V) Data analysis and interpretation: Ling Ye, Gendi Yin, Bo Tu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The present study was funded by the Guangdong Province Medical Science and Technology Research Foundation (Grant No. B2019132, NO. B2020025). By the Fundamental Research Funds for The Central University (Grant No.21619359). By the Project of Administration of Traditional Chinese Medicine of Guangdong Province of China (Grant No. 20191088).

Ethics approval and consent to participate

All animal procedures were conducted in accordance with the guidelines and regulations of the First Affiliated Hospital of Jinan University Ethics Committee (Guangdong, China).

ORCID iD

Ling Ye https://orcid.org/0000-0003-1078-063X

Availability of data and materials

All data used in this study are included in this published article.

References

1. Zhao F, Pu Y, Qian L, Zang C, Tao Z, Gao J. MiR-20a-5p promotes radio-resistance by targeting NPASt2 in nasopharyngeal cancer cells. Oncotarget. 2017;8:105873-105881.
2. Lin CH, Chiang MC, Chen YJ. STAT3 mediates resistance to anoikis and promotes invasiveness of nasopharyngeal cancer cells. Int J Mol Med. 2017;40:1549-1556.
3. Kuang CM, Fu X, Hua YJ, et al. BST2 confers cisplatin resistance via NF-kB signaling in nasopharyngeal cancer. Cell Death Dis. 2017;8:e2874.
4. Xu H, Zeng L, Guan Y, et al. High NEK2 confers poor prognosis and contributes to cisplatin-based chemotherapy resistance in nasopharyngeal carcinoma. J Cell Biochem. 2019;120:3547-3558.
5. Cao W, Du Y, Wang C, Xu L, Wu T. Cscs encoding chorismate synthase is a candidate gene for leaf variation mutation in cucumber. Breed Sci. 2018;68:571-581.
6. Sterzyńska K, Klejewski A, Wojtowicz K, et al. Mutual expression of ALDH1A1, LOX, and collagens in ovarian cancer cell lines as combined CSCs- and ECM-related models of drug resistance development. Int J Mol Sci. 2018;20:E54.
7. La Noce M, Paino F, Mele L, et al. HDAC2 depletion promotes osteosarcoma’s stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy. J Exp Clin Cancer Res. 2018;37:296.
8. Sotgia F, Ozsvari B, Fiorillo M, Francesco E, Bonuccelli G, Lisanti M. A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX. Cell Cycle. 2018;17:2091-2100.
9. Anorma C, Hedhli J, Bearrood TE, et al. Surveillance of cancer stem cell plasticity using an isoform-selective fluorescent probe for aldehyde dehydrogenase 1A1. ACS Cent Sci. 2018;4:1045-1055.
10. Levin AS. CSCs: regenerating optimism for osteosarcoma treatment. Oncotarget. 2018;9:31562-31563.
11. Boras-Granic K, Hamel PA. Wnt-signalling in the embryonic mammary gland. J Mammary Gland Biol Neoplasia. 2013;18:155-163.
12. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469-480.
13. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004;5:691-701.
14. Lin YC, You L, Xu Z, et al. Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochem Biophys Res Commun. 2006;341:635-640.
15. Morgan RG, Ridsdale JJ, Tonks A, Darley RL. Factors affecting the nuclear localization of beta-catenin in normal and malignant tissue. Cell Biochem. 2014;115:1351-1361.
16. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149:1192-1205.
17. MacDonald BT, He X. Frizzled and LRPs/6 receptors for Wnt/beta-catenin signaling. Cold Spring Harb Perspect Biol. 2012;4:a007880.
18. Wu G, Huang H, Garcia Abreu J, He X. Inhibition of GSK3 phosphorylation of beta-catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6. PLoS One. 2009; 4:e4926.
19. Zeng X, Tamai K, Doble B, et al. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature. 2005;438:873-877.
20. Fan KJ, Yang B, Liu Y, Tian XD, Wang B. Inhibition of human lung cancer proliferation through targeting stromal fibroblasts by dihydromyricetin. Mol Med Rep. 2017;16:9758-9762.
21. Kao SJ, Lee WJ, Chang JH, et al. Suppression of reactive oxygen species-mediated ERK and JNK activation sensitizes dihydromyricetin-induced mitochondrial apoptosis in human non-small cell lung cancer. Environ Toxicol. 2017;32:1426-1438.
22. Ji FJ, Tian XF, Liu XW, et al. Dihydromyricetin induces cell apoptosis via a p53-related pathway in AGS human gastric cancer cells. Genet Mol Res. 2015;14:15564-15571.
23. Wang Z, Sun X, Feng Y, et al. Dihydromyricetin reverses MRP2-mediated MDR and enhances anticancer activity induced by oxaliplatin in colorectal cancer cells. Anticancer Drugs. 2017;28:281-288.
24. Jiang L, Zhang Q, Ren H, et al. Dihydromyricetin enhances the chemosensitivity of nedaplatin via regulation of the p53/Bcl-2 pathway in hepatocellular carcinoma cells. PLoS One. 2015;10:e0124994.
25. Zhang W, Wang S, Yin H, et al. Dihydromyricetin enhances the osteogenic differentiation of human bone marrow mesenchymal stem cells in vitro partially via the activation of Wnt/β-catenin signaling pathway. Fundam Clin Pharmacol. 2016;30:596-606.
26. Gressette M, Vérlillaud B, Jimenez-Pailhès AS, et al. Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts. PLoS One. 2014;9:e91325.
27. Rios-Fuller TJ, Ortiz-Soto G, Lacourt-Ventura M, et al. Ganoderma lucidum extract (GLE) impairs breast cancer stem cells by targeting the STAT3pathway. Oncotarget. 2018;9:35907-35921.
28. Reineke L, Lam AP, Flozak AS, Varga J, Gottardi C. Adiponectin inhibits Wnt co-receptor, Lrp6, phosphorylation and β-catenin signaling. Biochem Biophys Res Commun. 2016;470(3):606-612.
29. Fan Y, Xue W, Schachner M, Zhao W. Honokiol eliminates glioma/glioblastoma stem cell-like cells via JAK-STAT3 signaling and inhibits tumor progression by targeting epidermal growth factor receptor. Cancers (Basel). 2018;11:E22.
30. Liu HW, Su YK, Bamodu OA, et al. The disruption of the β-Catenin/TCF-1/STAT3 signaling axis by 4-Acetylanthronquinonol B inhibits the tumorigenesis and cancer stem-cell-like properties of glioblastoma cells, in vitro and in vivo. Cancers (Basel). 2018;10:E491.
31. Li X, Zhao Z, Li M, et al. Sulforaphane promotes apoptosis, and inhibits proliferation and self-renewal of nasopharyngeal cancer cells by targeting STAT signal through miRNA-124-3p. Biomed Pharmacother. 2018;103:473-481.
32. Feng F, Chen A, Huang J, Xia Q, Chen Y, Jin X. Long non-coding RNA SNHG16 contributes to the development of bladder cancer via regulating miR-98/STAT3/β-catenin pathway axis. J Cell Biochem. 2018;119:9408-9418.
33. Christensen AG, Ehmsen S, Terp MG, et al. Elucidation of altered pathways in tumor-initiating cells of triple-negative breast cancer: a useful cell model system for drug screening. Stem Cells. 2017;35:1898-1912.
34. Satriyo PB, Bamodu OA, Chen JH, et al. Cadherin 11 inhibition downregulates β-catenin, deactivates the canonical WNT signalling pathway and suppresses the cancer stem cell-like phenotype of triple negative breast cancer. J Clin Med. 2019;8:E148.
35. Liu B, Du R, Zhou L, et al. miR-200c/141 Regulates breast cancer stem cell heterogeneity via targeting HIPK1/β-Catenin axis. Theranostics. 2018;8:5801-5813.
36. Zhang Y, Fan J, Fan Y, et al. The new 6q27 tumor suppressor DACT2, frequently silenced by CpG methylation, sensitizes nasopharyngeal cancer cells to paclitaxel and 5-FU toxicity via β-catenin/Cdc25c signaling and G2/M arrest. Clin Epigenetics. 2018;10:26.
37. Cheng Y. FEZF1-AS1 is a key regulator of cell cycle, epithelial-mesenchymal transition and Wnt/β-catenin signaling in nasopharyngeal carcinoma cells. Biosci Rep. 2019;39:BSR20180906.
38. Yan S, Zhou C, Zhang W, et al. beta-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett. 2008;271:85-97.
39. Kawada M, Seno H, Uenoyma Y, et al. Signal transducers and activators of transcription 3 activation is involved in nuclearaccumulation of beta-catenin in colorectal cancer. Cancer Res. 2006;66:2913-2917.